CRISPR 2.0 and the Future of Gene Therapies

The gene therapy sector is undergoing a paradigm shift from simple transgene addition to precise CRISPR-based editing, driven by recent FDA approvals and a pipeline projecting dozens of Phase 3 trials this year. Despite significant progress in developing base editors and expanding delivery vectors, the industry faces critical bottlenecks in manufacturing scalability and achieving organ-specific targeting without immunogenicity. Successful organizations are distinguishing themselves by combining rigorous engineering mindsets with interdisciplinary teams to optimize modalities and automate production for a future of millions of patients.